Allergic rhinitis
Conditions
Interventions
AR children group :NA
Healthy control group:NA
Sponsors
Huzhou Center Hospital
Eligibility
Sex/Gender
All
Age
5 Years to 17 Years
Inclusion criteria
Inclusion criteria: Children in the AR group: 1.Meeting the above-mentioned diagnostic criteria for allergic rhinitis (AR); 2.Enrolled children aged between 5 and 17 years old; 3.No history of asthma attacks or other allergic diseases within 6 months prior to enrollment; 4.Immediate family members (or legal guardians) of the participants have provided consent, signed the informed consent form, and the participants voluntarily agree to participate in the study. Healthy control children: 1. Good mental condition, no history of allergic diseases and family history; 2. Age 7~17 years old; 3. Those who can cooperate with the completion of the study.
Exclusion criteria
Exclusion criteria: Children in the AR group: 1.Diagnosed with other allergic diseases requiring long-term medication that cannot be discontinued simultaneously; 2.Presence of deviated nasal septum, or concurrent sinusitis, nasal cavity masses, or other nasal mucosal lesions detected by nasal endoscopy; 3.Suspected or confirmed history of drug abuse; 4.Currently participating in other clinical studies or deemed unsuitable for participation by the investigator; 5.Complicated by other severe primary diseases such as cardiovascular and cerebrovascular diseases, hepatic, renal, or hematopoietic system diseases, autoimmune diseases, congenital genetic metabolic diseases, or psychiatric disorders; 6.Children with AR currently receiving specific immunotherapy; 7.Children whose family members or legal guardians disagree or are unable to cooperate. Healthy control children: 1. Previous history of AR or family history of AR; 2. Those who have poor compliance and are unable to cooperate with the completion of the study; 3. Those who are participating in other clinical studies or are considered inappropriate by the investigator to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of lncRNA-NEAT1;Expression of miR-142-5p;Expression of CDK5; | — |
Countries
China
Contacts
Public ContactYang Lihong
Huzhou Center Hospital
Outcome results
None listed